Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Comment by lscfaon Jan 28, 2022 6:26pm
101 Views
Post# 34373384

RE:Willow's future stock price

RE:Willow's future stock price

At Sept 30 co. had $0.29/sh in cash but burning $4 mil/qtr ($0.03/sh) in cash, mostly on R&D. Question is does that pace of R&D continue or slow.  If they burn it all up to get to commercialization then they need to generate $13 million/yr to justify current share price.

 

 

Revenue

13

70% Gross margin

9.1

Cash exp

(5)

Ebitda

4.1

Shs 

123

Ebitda/sh

$0.033

Multiple

12

Sh value

$0.400

 






"With approximately $35.7 million in cash as of September 30, 2021, Willow is well positioned to fund its operations to commercialization."
 

<< Previous
Bullboard Posts
Next >>